|
1.
|
|
11 p, 822.0 KB |
SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
/
González-del-Alba, Aránzazu (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
De Velasco, G. (Hospital 12 de Octubre (Madrid)) ;
Lainez, N. (Complejo Hospitalario de Navarra) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Morales-Barrera, Rafael (Vall d'Hebron Institut d'Oncologia) ;
Muñoz-Langa, J. (Hospital Universitari i Politècnic La Fe (València)) ;
Pérez-Valderrama, B. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Basterretxea, Laura (Hospital Donostia-Donostia Ospitalea) ;
Caballero, C. (Hospital General Universitario de Valencia) ;
Vazquez, S. (Hospital Universitario Lucus Augusti (Lugo)) ;
Universitat Autònoma de Barcelona
The goal of this article is to provide recommendations about the management of muscle-invasive (MIBC) and metastatic bladder cancer. New molecular subtypes of MIBC are associated with specific clinical-pathological characteristics. [...]
2019 -  10.1007/s12094-018-02001-x
Clinical & Translational Oncology, Vol. 21 Núm. 1 (25 2019) , p. 64-74
|
|
|
2.
|
|
12 p, 144.7 KB |
Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
/
Puente, J. (Medical Oncology Department. Hospital Clínico San Carlos. Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC). CIBERONC) ;
Anido, Urbano (Complejo Hospitalario Universitario de Santiago de Compostela) ;
Climent, M.Á. (Instituto Valenciano de Oncología (IVO)) ;
Gonzalez-Billalabeitia, E. (Universidad Católica San Antonio de Murcia-UCAM) ;
Lainez, N. (Complejo Hospitalario de Navarra) ;
Lambea, Julio (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Mendez-Vidal, M.J. (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Montesa, Álvaro (Hospital Regional Universitario de Málaga) ;
Rodriguez, A. (Hospital Universitario de León) ;
Zambrana, C. (Hospital Universitario Infanta Sofía (San Sebastián de los Reyes)) ;
González-del-Alba, A. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Universitat Autònoma de Barcelona
Our aim was to provide practical recommendations on the management of patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel plus androgen-deprivation therapy (ADT) or abiraterone plus ADT. [...]
2020 - 10.1177/1758835920920067
Therapeutic Advances in Medical Oncology, Vol. 12 (2020)
|
|
|
3.
|
|
8 p, 823.8 KB |
SEOM clinical guidelines in hereditary breast and ovarian cancer (2019)
/
González-Santiago, S. (Hospital Universitario San Pedro de Alcántara) ;
Ramon y Cajal, Teresa (Institut d'Investigació Biomèdica Sant Pau) ;
Aguirre, Elena (Hospital Quirónsalud) ;
Alés-Martínez, J.E. (Hospital Nuestra Señora de Sonsoles (Àvila)) ;
Andrés, R. (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Balmaña Gelpí, Judith (Hospital Universitari Vall d'Hebron) ;
Graña, B. (Complexo Hospitalario Universitario (CHUAC)) ;
Herrero, A. (Hospital Universitario Miguel Servet (Saragossa)) ;
Llort, Gemma (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
González-del-Alba, A. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
the SEOM Hereditary Cancer Working Group ;
Universitat Autònoma de Barcelona
Mutations in BRCA1 and BRCA2 high penetrance genes account for most hereditary breast and ovarian cancer, although other new high-moderate penetrance genes included in multigene panels have increased the genetic diagnosis of hereditary breast and ovarian cancer families by 50%. [...]
2020 - 10.1007/s12094-019-02262-0
Clinical & Translational Oncology, Vol. 22 Núm. 2 (january 2020) , p. 193-200
|
|
|
4.
|
|
9 p, 1.2 MB |
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide
/
Fernandez-Perez, María P. (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Perez-Navarro, Enrique (Hospital Universitario 12 de Octubre (Madrid)) ;
Alonso-Gordoa, Teresa (Hospital Universitario Ramón y Cajal (Madrid)) ;
Conteduca, Vincenza (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) "Dino Amadori" IRCCS) ;
Font, Albert (Institut Català d'Oncologia) ;
Vázquez-Estévez, Sergio (H. Universitario Lucus Augusti) ;
González-del-Alba, Aránzazu (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Wetterskog, Daniel (Paul O'Gorman Building) ;
Antonarakis, Emmanuel S. (Johns Hopkins University School of Medicine) ;
Mellado, Begona (Hospital Clínic i Provincial de Barcelona) ;
Fernandez-Calvo, Ovidio (Complejo Hospitalario Universitario Ourense) ;
Méndez-Vidal, María J. (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Climent, Miguel Ángel (Fundació Institut Valencià d'Oncologia) ;
Duran, Ignacio (Instituto de Biomedicina de Sevilla) ;
Gallardo, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Rodriguez Sanchez, Angel (Hospital Universitario de León) ;
Santander, Carmen (Hospital Universitario Miguel Servet (Saragossa)) ;
Sáez, Maria I. (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Puente, Javier (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Tudela, Julian (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Martínez, Alberto (Biobanco de la región de Murcia) ;
López-Andreo, Maria J. (SAI-IMIB-Universidad de Murcia) ;
Padilla, José (Hospital Universitario Morales Meseguer) ;
Lozano, Rebeca (Instituto de Investigación Biomédica de Málaga) ;
Hervas, David (Instituto de Investigación Sanitaria La Fe) ;
Luo, Jun (Johns Hopkins University School of Medicine) ;
De Giorgi, Ugo (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) "Dino Amadori" IRCCS) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Attard, Gerhardt (Paul O'Gorman Building) ;
Grande, Enrique (MD Anderson Cancer Center Madrid) ;
Gonzalez-Billalabeitia, Enrique (Universidad Católica San Antonio de Murcia-UCAM) ;
Universitat Autònoma de Barcelona
There is a considerable need to incorporate biomarkers of resistance to new antiandrogen agents in the management of castration-resistant prostate cancer (CRPC). We conducted a phase II trial of enzalutamide in first-line chemo-naïve asymptomatic or minimally symptomatic mCRPC and analyzed the prognostic value of TMPRSS2-ERG and other biomarkers, including circulating tumor cells (CTCs), androgen receptor splice variant (AR-V7) in CTCs and plasma Androgen Receptor copy number gain (AR-gain). [...]
2022 - 10.1002/pros.24469
The Prostate, Vol. 83 (december 2022)
|
|
|
5.
|
|
9 p, 402.4 KB |
Gender influence on work satisfaction and leadership for medical oncologists : a survey of the Spanish Society of Medical Oncology (SEOM)
/
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Ayala de la Peña, Francisco (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ;
García Campelo, Rosario G. (Complexo Hospitalario Universitario) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
García Donas, J (Centro Integral Oncológico Clara Campal (CIOCC)) ;
González-del-Alba, Aránzazu (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
González-Flores, Encarnación (Hospital Universitario Virgen de las Nieves (Granada)) ;
Hidalgo, Julia (Hospital Lluis Alcanyís de Xativa) ;
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Rodríguez-Lescure, Álvaro (Hospital General Universitario de Elche) ;
Safont, María José (Consorcio Hospital General Universitario Valencia) ;
Santaballa, Ana (Hospital Universitari i Politècnic La Fe (València)) ;
Villacampa Javierre, Guillermo (Vall d'Hebron Institut d'Oncologia) ;
Vera, Ruth (Complejo Hospitalario de Navarra) ;
Garrido, Pilar (Hospital Universitario Ramón y Cajal (Madrid))
Background: Women represent an increasing proportion of the oncology workforce; however, globally this does not translate into leadership roles, reflecting disparities in career opportunities between men and women. [...]
2021 - 10.1016/j.esmoop.2021.100048
ESMO open, Vol. 6 Núm. 2 (april 2021) , p. 100048
|
|
|
6.
|
|
17 p, 1.2 MB |
Recent advances in the management of patients with non-muscle-invasive bladder cancer using a multidisciplinary approach : Practical recommendations from the spanish oncology genitourinary (sogug) working group
/
Rubio-briones, José (Hospital Vithas Valencia 9 de Octubre) ;
Algaba, Ferran (Institut d'Investigació Biomèdica Sant Pau) ;
Gallardo, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Marcos-Rodríguez, José Antonio (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Climent, Miguel Ángel (Medical Oncology Service. Fundación Instituto Valenciano de Oncología) ;
Gomez-Caamaño, Antonio (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ;
Garcia Vicente, Ana M. (Spanish Oncology Genitourinary) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Rodriguez Antolín, Alfredo (Spanish Oncology Genitourinary) ;
Sanz, Julian (Spanish Oncology Genitourinary) ;
Vera González, Maria Almudena (Spanish Oncology Genitourinary) ;
González-del-Alba, Aránzazu (Spanish Oncology Genitourinary) ;
Conde Moreno, Antonio José (Spanish Oncology Genitourinary) ;
González-Haba, Eva (Spanish Oncology Genitourinary) ;
González-Peramato, Pilar (Spanish Oncology Genitourinary) ;
Linares Espinós, Estefania (Spanish Oncology Genitourinary) ;
López-Beltran, Antonio (Spanish Oncology Genitourinary) ;
Pelechano, Paula (Spanish Oncology Genitourinary) ;
Garrido, Marga (Spanish Oncology Genitourinary) ;
Gironés Sarrió, Regina (Spanish Oncology Genitourinary) ;
Zapatero, Almudena (Spanish Oncology Genitourinary) ;
Arranz Alija, Jose Ángel (Spanish Oncology Genitourinary) ;
Universitat Autònoma de Barcelona
On the basis of the discussion of the current state of research on relevant topics of non-muscle-invasive bladder cancer (NMIBC) among a group of experts of the Spanish Oncology Gen-itourinary (SOGUG) Working Group, recommendations were proposed to overcome the challenges posed by the management of NMIBC in clinical practice. [...]
2021 - 10.3390/cancers13194762
Cancers, Vol. 13 Núm. 19 (October 2021) , p. 4762
|
|
|
7.
|
|
11 p, 805.4 KB |
SEOM clinical guidelines for the treatment of advanced prostate cancer (2020)
/
González-del-Alba, Aránzazu (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Méndez-Vidal, M. J. (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Vazquez, S. (Hospital Universitario Lucus Augusti (Lugo)) ;
Castro, E. (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Climent, Miguel Ángel (Fundació Institut Valencià d'Oncologia) ;
Gallardo, Eduard (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Gonzalez-Billalabeitia, Enrique (Universidad Católica San Antonio de Murcia) ;
Lorente, D. (Consorci Hospitalari Provincial de Castelló) ;
Maroto Rey, Pablo. (Institut d'Investigació Biomèdica Sant Pau) ;
Arranz Alija, Jose Ángel (Hospital General Universitario Gregorio Marañón) ;
Universitat Autònoma de Barcelona
The treatment of advanced prostate cancer has evolved due to recent advances in molecular research and new drug development. Dynamic aberrations in the androgen receptor, DNA repair genes, PTEN-PI3K, and other pathways drive the behavior of advanced prostate cancer allowing a better selection of therapies in each patient. [...]
2021 - 10.1007/s12094-021-02561-5
Clinical & Translational Oncology, Vol. 23 (february 2021) , p. 969-979
|
|
|
8.
|
|
6 p, 1.4 MB |
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
/
Conteduca, Vincenza (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) ;
Jayaram, Anuradha (University College London Cancer Institute) ;
Romero-Laorden, Nuria (Hospital Universitario de la Princesa (Madrid)) ;
Wetterskog, Daniel (University College London Cancer Institute) ;
Salvi, Samanta (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) ;
Gurioli, Giorgia (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) ;
Scarpi, Emanuela (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) ;
Castro, Elena (Hospital Universitario Quirón, Madrid) ;
Marin-Aguilera, Mercedes (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Lolli, Cristian (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) ;
Schepisi, Giuseppe (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) ;
Maugeri, Antonio (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) ;
Wingate, Anna (University College London Cancer Institute) ;
Farolfi, Alberto (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) ;
Casadio, Valentina (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) ;
Medina, Ana (Centro Oncológico de Galicia) ;
Puente, Javier (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Vidal, Mª José Méndez (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Morales-Barrera, Rafael (Vall d'Hebron Institut d'Oncologia) ;
Villa-Guzmán, Jose C. (Hospital General Universitario de Ciudad Real) ;
Hernando, Susana (Hospital Universitario Fundación Alcorcón) ;
Rodriguez-Vida, Alejo (Hospital del Mar (Barcelona, Catalunya)) ;
González-del-Alba, Aránzazu (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Mellado, Begoña (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Gonzalez-Billalabeitia, Enrique (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Olmos, David (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Attard, Gerhardt (University College London Cancer Institute) ;
De Giorgi, Ugo (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) ;
Universitat Autònoma de Barcelona
Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its relevance in the context of taxane chemotherapy is unknown. [...]
2019 - 10.1016/j.eururo.2018.09.049
European Urology, Vol. 75 (march 2019) , p. 368-373
|
|
|
9.
|
|
9 p, 341.6 KB |
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
/
Conteduca, Vincenza (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Wetterskog, Daniel (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Sharabiani, M. T. A. (Royal Marsden NHS Foundation Trust. Research Data Management and Statistics Unit) ;
Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ;
Fernandez Perez, M. P. (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Jayaram, Anuradha (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Salvi, S. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Romanel, A. (Università di Trento. Centro di Biologia Integrata) ;
Lolli, C. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Casadio, Valentina (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Gurioli, Giorgia (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Amadori, D. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Font Guiteras, Antoni (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Vazquez Estevez, S. (Hospital Universitario Lucus Augusti (Lugo)) ;
González-del-Alba, Aránzazu (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Mellado, B. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Fernandez Calvo, O. (Complejo Hospitalario Universitario de Ourense) ;
Méndez Vidal, M. J. (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Climent, Miguel Ángel (Fundació Institut Valencià d'Oncologia) ;
Durán, Ignacio (Instituto de Biomedicina de Sevilla) ;
Gallardo, Eduard (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Rodríguez Sánchez, Ángel (Hospital Universitario de León) ;
Santander, C. (Hospital Universitario Miguel Servet (Saragossa)) ;
Sáez, M. I. (Hospital Regional Universitario de Málaga) ;
Puente, J. (Hospital Clínico San Carlos (Madrid)) ;
Gasi Tandefelt, D. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Wingate, Anna (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Dearnaley, David (Royal Marsden NHS Foundation Trust. Academic Urology Unit) ;
Demichelis, F. (Università di Trento. Centro di Biologia Integrata) ;
De Giorgi, Ugo (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Gonzalez-Billalabeitia, Enrique (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Attard, Gerhardt (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Spanish Oncology Genitourinary Group ;
Universitat Autònoma de Barcelona
Background: There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC. [...]
2017
Annals of oncology, Núm. 28 (2017) , p. 1508-1516
|
|
|
10.
|
|
10 p, 402.2 KB |
SEOM clinical guideline for treatment of kidney cancer (2017)
/
Gallardo, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Méndez-Vidal, M. J. (Instituto Maimónides de Investigación Biomédica de Córdoba) ;
Pérez-Gracia, J. L. (Clínica Universidad de Navarra) ;
Sepúlveda-Sánchez, J. M. (Hospital Universitario 12 de Octubre (Madrid)) ;
Campayo, M. (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Chirivella, Isabel (Hospital Clínic Universitari (València)) ;
Garcia del Muro, Xavier (Institut d'Investigació Biomèdica de Bellvitge) ;
González-del-Alba, Aránzazu (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ;
Suárez, Cristina (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. [...]
2017 - 10.1007/s12094-017-1765-4
Clinical & Translational Oncology, Vol. 20 (november 2017) , p. 47-56
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
